Home » Blog » The heart of the internet
The 503A pharmacies are state-licensed facilities that follow USP guidelines to prepare customized medications for specific patients. The 503B outsourcing facilities produce compounded drugs in bulk and are registered with the FDA. Insurance coverage varies and will affect many patients’ choices about going on weight loss medications. As with many medications, some weight loss drugs have been on the market longer, have generic alternatives, and tend to be more affordable. In 2025, the price of lyrica phentermine-topiramate ER (Qsymia) combination became available in generic form.
The risks of addiction to prescription drugs rise when they are used in means other than prescribed (e.g. at higher doses, by other routes of administration, or mixed with alcohol or other drugs) (NIDA, 2014). A prospective cross-sectional observational study design was used, which was conducted at different community pharmacies in Amman-Jordan. During the study period (November 2016–January 2017), a total 77 requests for pregabalin were observed from 14 pharmacies.
We are one of the nation’s most trusted resources for medications and prescriptions because patients and their physicians know they can count on the quality of the products we make. Enhance your clinical software and transform healthcare delivery with evidence-based, structured drug information. With prescription medications, a healthcare professional can weigh all factors affecting the patient’s lifestyle and BMI and monitor progress and side effects. This relationship can allow for dosage adjustments or alternative medications if one seems like a better fit for the patient. More detailed information about each of the above weight loss medications can be found in the latest edition of Obesity Medicine Association’s Obesity Algorithm®.
This injectable triple receptor agonist targets GLP-1, GIP, and glucagon. The study included patients with obesity and knee osteoarthritis with trial endpoints examining weight loss and reduction in knee pain. In this trial, participants lost up to 28.7% of body weight at 68 weeks. We are likely to continue to see clinical trials include treatment of adiposity-related diseases as a component of obesity medication investigations. In 2017 another announcement was released in Jordan to emphasize the obligation on not to supply samples of drugs containing this substance or grant quantities of incentives on the quantities sold of this medicine (JFDA, 2017). Despite this announcement the pregabalin products still can be sold without a prescription and without fear of any legal accountability.